Clinical Trials Browser

Phase 1/2 × Carcinoma × Nivolumab × Clear all

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT04151563 2023-12-19

CheckMate 79X

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03633110 2022-04-19

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Phase 1/2 Completed

24 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms

Clinical Trials

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

CheckMate 79X

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine